3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Active not recruiting
3
Completed
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
19
Gastrointestinal
5
Thoracic
4
CNS
3
Tumor-Agnostic
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
3
Brain Neoplasms
3
Interventions
Temozolomide
59
Radiotherapy
37
Magnetic Resonance Spectroscopy
32
Radiosurgery
27
Specimen Handling
23
Cyclophosphamide
21
pembrolizumab
20
Nivolumab
20
Radiation
17
Carboplatin
12
Biopsy
12
Bevacizumab
11
Vincristine
10
Ipilimumab
10
Cisplatin
10
X-Rays
9
Lomustine
8
Irinotecan
8
Immunoglobulin G
8
Etoposide
8
trametinib
7
Disulfides
7
AZD 6244
7
pertuzumab
6
atezolizumab
6
abemaciclib
6
Topotecan
6
Proton Therapy
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
trastuzumab deruxtecan
×
CNS
×
Clear all
NCT04739761
2026-05-12
DESTINY-B12
AstraZeneca
Phase 3
Active not recruiting
506 enrolled
27 charts
NCT06048718
2026-05-08
TUXEDO-4
MedSIR
Phase 2
Active not recruiting
28 enrolled
NCT04538742
2025-12-08
DB-07
AstraZeneca
Phase 1/2
Active not recruiting
245 enrolled